Anti-chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal antibody immunoconjugates for ovarian cancer therapy. - Concepedia

Concepedia

Publication | Closed Access

Anti-chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal antibody immunoconjugates for ovarian cancer therapy.

20

Citations

0

References

1995

Year

Christos Kosmas, Anthony Maraveyas, Calvin S. R. Gooden, D Snook, A A Epenetos

Abstract

CITC-DTPA is immunogenic in patients after intraperitoneal administration of 90Y-CITC-DTPA labeled MAbs. Self-limiting clinical side effects consistent with a serum sickness-like immune reaction were observed in 5 of 12 patients.